Oncogen

Sanofi

Cetus Corporation

Oncogen Limited Partnership

Diane Horn

Peter S Linsley

Joseph P Brown

Karl E Hellstrom

Ingegerd E Hellstrom

Karl Erik Hellstrom

David B Ring

Arthur E Frankel

Vincent W Ochs

Vincent Ochs

Joseph Patrick Brown

Novel hybridoma cell lines producing monoclonal antibodies reactive with purified mucin antigens from normal and tumor sources are generated using mucins, including purified mucins from tumor sources. Epitopes on mucin antigens from normal and tumor sources are demonstrated to be distinct, using these new antibodies. The antibodies may be useful alone or in combination, in the diagnosis and treatment of cancer including malignancies of the breast and lung.

Method for detecting cancer using monoclonal antibodies to new mucin

Hybridomas producing monoclonal antibodies to new mucin epitopes

A method for treating serum samples to remove sialic acid from ligands to expose binding sites to enhance immunological binding, for use in assays and to generate novel anti-ligands is described. The method includes treatment of serum using neuraminidase.

Method for increasing the sensitivity of assays for target ligand

The present invention is concerned with novel monoclonal antibodies which define a glycolipid antigen associated with human non-small cell lung carcinomas ('NSCLC') and certain other human carcinomas. The antibodies bind to normal human cells to a much lesser degree than to tumor cells. The antibodies find use in diagnostic methods such as the detection of malignant cells associated with NSCLC and in therapeutic methods. The invention also comprises a method for determining the presence of a malignant condition in lung tissue and other human tissue. The method involves examining the human tissue for the presence of a glycolipid antigen having the characteristics of a ganglio-N-triosylceramide.

Monoclonal antibodies for treatment of human non-small cell lung

The present invention is concerned with novel monoclonal antibodies which define a gylcolipid antigen associated with human non-small cell lung carcinomas ('NSCLC') and certain other human carcinomas. The antibodies bind to normal human cells to a much lesser degree than to tumor cells. The antibodies find use in diagonostic methods such as the detection of malignant cells associated with NSCLC and in therapeutic methods. The invention also comprises a method for determining the presence of a malignant condition in lung tissue and other human tissue. The method involves examining the human tissue for the presence of a glycolipid antigen having the characteristics of a ganglio-N-triosylceramide.

Monoclonal antibodies to the L6 glycolipid antigenic determinant found

The present invention is concerned with novel monoclonal antibodies which define a glycolipid antigen associated with human non-small cell lung carcinomas ('NSCLC') and certain other human carcinomas. The antibodies bind to normal human cells to a much lesser degree than to tumor cells. The antibodies find use in diagnostic methods such as the detection of malignant cells associated with NSCLC and in therapeutic methods. Also disclosed in a novel glycolipid antigen. The invention also comprises a method for determining the presence of a malignant condition in lung tissue and other human tissue. The method involves examining the human tissue for the presence of a glycolipid antigen having the terminal carbohydrate sequence: GalNAc.beta.l.fwdarw.4Gal.beta.l.fwdarw.3GalNAc.beta.l.fwdarw.4Gal.beta.l. fwdarw.R.

Monocolonal antibodies and antigen for human non-small cell lung

The present invention is concerned with two novel monoclonal antibodies which define carbohydrate antigens associated with human non-small cell lung carcinomas ('NSCLC') and certain other human carcinomas. The antibodies bind to normal human cells to a much lesser degree than to tumor cells. The antibodies find use in diagnostic methods such as the detection of malignant cells associated with NSCLC and in therapeutic methods. The invention also comprises a method for determining the presence of a malignant condition in the lung of a subject. The method involves examining tissue from the subject for the presence of antigens which are Le.sup.x or Le.sup.y antigen or which have the characteristics of Le.sup.y and Le.sup.x.

Method, monoclonal antibody, and monoclonal antibody fragments for

Methods are disclosed for detecting, staging and monitoring breast cancer. The methods involve determining the amount of certain antigens, designated W1 and W9, in serum via quantitative immunoassays using anti-W1 or anti-W9 monoclonal antibodies. The amount detected is compared with amounts of the antigen found in normal sera, sera from breast cancer patients of predetermined stage, or other samples of the patient's own serum, depending upon the purpose of the assay.

Assay for human breast cancer

The present invention is concerned with novel monoclonal antibodies which define antigens associated with human non-small cell lung carcinomas ('NSCLC'). The antibodies bind to normal human cells to a lesser degree than to tumor cells. The antibodies find use in diagnostic methods such as the detection of malignant cells associated with NSCLC and in therapeutic methods.

Growing community of inventors

Seattle, WA, United States of America

Diane Horn